Uptake and retention of platinum in patients undergoing cisplatin therapy.

Results of in vivo measurements of the platinum concentration in kidneys and tumours of patients treated with cisplatin for testicular carcinoma, head and neck tumours and brain tumours are presented. The measurements were performed with an x-ray fluorescence technique. Our earlier studies have shown that maximum platinum levels in kidneys were reached 3-4 h after an intravenous injection of cisplatin. The present study showed that, at that time, the ratio between the concentration of platinum in kidney and in blood serum was 22 +/- 7 (+/- 1 S.D.). Between 24 and 72 h after administration this ratio was 10 +/- 3, as shown in another group of patients. Measurements of platinum concentration in brain tumours showed varying maximum uptake, between 14 and 40 micrograms/g, 5-15 h after administration. There was an indication that radiotherapy may increase the uptake of cisplatin in normal brain tissue. The technique described can be used for further studies of the platinum concentration in tumours and risk organs in connection with cisplatin therapy. Such studies are needed to find out how to improve the therapeutic effects and lower the toxic ones.

[1]  J. Brown,et al.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. III. Cis-diamminedichloroplatinum. , 1979, International journal of radiation oncology, biology, physics.

[2]  E. Glatstein,et al.  Summary of investigations on platinum compounds and radiation interactions. , 1979, International journal of radiation oncology, biology, physics.

[3]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.

[4]  P. Twentyman,et al.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. VI. BCNU. , 1979, International journal of radiation oncology, biology, physics.

[5]  A. Guarino,et al.  Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. , 1976, Cancer research.

[6]  R. P. Spencer,et al.  The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  N. Hill,et al.  Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. , 1975, Cancer chemotherapy reports.

[8]  B. Unsgaard,et al.  A method for in vivo analysis of platinum after chemotherapy with cisplatin. , 1988, Physics in medicine and biology.

[9]  S. Strother,et al.  [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  C. Kovacs,et al.  Therapeutic potentiation of combined cis-dichlorodiammineplatinum (II) and irradiation by ICRF-159. , 1979, International journal of radiation oncology, biology, physics.

[11]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[12]  Smith Hs,et al.  Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man. , 1974 .